SCHEMBL6976827

SCHEMBL6976827

CC(C)(C)OC(=O)N1CCN(c2ccc(CC(=O)O)cc2F)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.50
MAPT P10636 6/20 0.49
ALDH1A1 P00352 3/20 0.49
LMNA P02545 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
NPC1 O15118 1/20 0.49
HPGD P15428 1/20 0.49
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49
MAPK1 P28482 1/20 0.49
HSD17B10 Q99714 1/20 0.49
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
POLB P06746 1/20 0.46
ACHE P22303 1/20 0.45
GPR119 Q8TDV5 4/20 0.44
CYP2C19 P33261 1/20 0.44
GRM5 P41594 1/20 0.44
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31341976 0.88 L3MBTL1 (0.48) L3MBTL1MAPTALDH1A1LMNANPSR1
SCHEMBL6970222 0.88 L3MBTL1 (0.48) L3MBTL1MAPTALDH1A1LMNANPSR1
SCHEMBL8250638 0.88 L3MBTL1 (0.52) L3MBTL1MAPTALDH1A1LMNANPSR1
SCHEMBL8257190 0.87 L3MBTL1 (0.51) L3MBTL1MAPTALDH1A1LMNANPSR1
SCHEMBL27225086 0.86 L3MBTL1 (0.57) L3MBTL1MAPTALDH1A1LMNANPSR1
SCHEMBL29707420 0.86 L3MBTL1 (0.50) L3MBTL1MAPTALDH1A1LMNANPSR1
SCHEMBL8259475 0.86 L3MBTL1 (0.50) L3MBTL1MAPTALDH1A1LMNANPSR1
SCHEMBL22957454 0.86 L3MBTL1 (0.50) L3MBTL1MAPTALDH1A1LMNANPSR1
SCHEMBL8257445 0.85 L3MBTL1 (0.49) L3MBTL1MAPTALDH1A1LMNANPSR1
SCHEMBL13344713 0.84 L3MBTL1 (0.54) L3MBTL1MAPTALDH1A1LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1107756-A4 NOVEL ISOXAZOLINONE ANTIBACTERIAL AGENTS BRISTOL MYERS SQUIBB CO (US) 2003-02-26 EP disclosed
US-20020094984-A1 Novel isoxazolinone antibacterial agents SNYDER LAWRENCE B (US) 2002-07-18 US disclosed
US-6420349-B1 POTENT ANTIBIOTIC ACTIVE AGAINST GRAM-POSITIVE BACTERIA; ANIMAL FEED;FOOD PRESERVATIVES; WATERBASED PAINTS; WHITE WATER OF PAPER MILLS; DISINFECTANTS FOR MEDICAL AND DENTAL EQUIPMENT BRISTOL-MYERS SQUIBB COMPANY 2002-07-16 US disclosed
EP-1107756-A1 NOVEL ISOXAZOLINONE ANTIBACTERIAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2001-06-20 EP disclosed
WO-2000010566-A1 NOVEL ISOXAZOLINONE ANTIBACTERIAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2000-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020094984-A1 Novel isoxazolinone antibacterial agents RPS4X, RPS4Y1, CYP51A1 L3MBTL1 1975/4885MAPT 4521/4885ALDH1A1 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.